# Nutex Health Inc.: Form 10-K for the period ended Dec 31, 2018

- Company: [Nutex Health Inc.](/companies/nutx.md) (CIK 1479681)
- Form: 10-K
- Filed: 2019-04-16
- Accepted by EDGAR: Apr 16, 2019, 16:46 ET
- Period: 2018-12-31
- Accession: 0001607062-19-000159
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1479681/000160706219000159/igmb123118form10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1479681/000160706219000159/

## Business

As filed, 14,132 characters.

### HISTORY

We were incorporated in the State of Delaware under the name BigVault.com Inc. on April 13, 2000. On April 18, 2000, we merged with BigVault.com, Inc., a New York corporation with which we were affiliated. We survived the merger, and on December 19, 2000 changed our name to bigVAULT Storage Technologies, Inc. At that time we were in the business of providing remote, internet-based storage vaulting services and related ancillary services to end users and resellers (the “Vault Business”).

On February 28, 2006 we sold all of our assets to Digi-Data Corporation (“DDC”), an unrelated third party, pursuant to the terms of an Asset Purchase Agreement dated December 21, 2005 (the “APA”), a copy of which is filed herewith as an exhibit. As consideration for our transfer of assets under the APA, DDC paid certain of our liabilities and agreed to make certain quarterly and annual revenue sharing payments to us, as is further described below. Mr. Salerno and Ms. Luqman accepted employment with DDC in senior management positions post closing, and continued to work for DDC until February 2009. As of March 1, 2009 Mr. Salerno and Ms. Luqman returned to their full time management roles with the Company.

On April 5, 2006, we changed our name to iGambit Inc.

On October 1, 2009, we acquired the assets of Jekyll Island Ventures, Inc., a New York corporation doing business as Gotham Photo Company (“Jekyll”) through our wholly owned subsidiary Gotham Innovation Lab, Inc., a New York corporation (“Gotham”).

On November 4, 2015, we consummated the acquisition of Wala, Inc. doing business as ArcMail Technology (ArcMail) in accordance with a Stock Purchase Agreement (the “ArcMail Purchase Agreement”) by and among Wala, Inc. doing business as ArcMail Technologies (“ArcMail”), Rory T. Welch (the “Seller”) and the Company. Pursuant to the Stock Purchase, the total consideration to be paid for the outstanding capital stock of ArcMail is 11,500,000 shares of the Company’s Common stock. 10,500,000 shares of iGambit’s Common stock to the Seller, and/or Seller’s designees at Closing and the Holdback Amount of 1,000,000 shares of the iGambit’s Common stock to be held in Escrow and paid to the Seller on later of (i) the first (1st) anniversary of completion of the first audit of Purchaser after the Closing, or (ii) that date which is twelve (12) months from the Closing, provided that in the event iGambit or the Purchaser has any claims for indemnification against the Seller under the Purchase Agreement, Purchaser shall continue to withhold the portion of the Holdback Amount subject to such claims until the parties fully and finally resolve such claims.

The ArcMail Purchase Agreement was disclosed on the Company’s current report on Form 8-K filed on November 10, 2015.

On November 5, 2015, through our wholly owned subsidiary Gotham Innovation Lab, Inc. (“Gotham”), we completed the sale of certain assets of Gotham to VHT Inc. (“VHT”) in accordance with an Asset Purchase Agreement (the “VHT Purchase Agreement”) by and between Gotham and VHT. Pursuant to the Purchase Agreement the Company received $600,000 in consideration, $400,000 of the consideration was received at closing and the remaining $200,000 portion of the consideration is subject to twelve (12) equal monthly payments beginning January 2016. The sale included certain of the assets of the Gotham, including the Elliman customer agreement, all customer accounts, all vendor agreements and all the intellectual property.

The VHT Purchase Agreement was disclosed on the Company’s current report on Form 8-K filed on November 11, 2015.

On February 14, 2017, we consummated the acquisition of HubCentrix, Inc. (HubCentrix) in accordance with a Stock Exchange Agreement (the “Exchange Agreement”) by and among HubCentrix, Jerry Robinson, Mary-Jo Robinson, Kathleen Shepherd, Edwin Shepherd, Nora Minor,,and Sandra Gacio (the “Hub Shareholders”) and the Company. Pursuant to the Exchange Agreement, the total consideration to be paid for the outstanding capital stock of HubCentrix is 15,000,000 shares of the Company’s Common stock. 13,500,00 shares of iGambit’s Common stock to the Hub Shareholders at Closing and the Holdback Amount of 1,500,000 shares of the iGambit’s Common stock to be held restricted and paid to the Seller on later of (i) the first (1st) anniversary of completion of the first audit of Purchaser after the Closing, or (ii) that date which is twelve (12) months from the Closing, provided that in the event the Company has any claims for indemnification against the HubCentrix under the Exchange Agreement, the Company shall continue to withhold the portion of the Holdback Amount subject to such claims until the parties fully and finally resolve such claims.

The HubCentrix Exchange Agreement was disclosed on the Company’s current report on Form 8-K filed on February 15, 2017.

On March 27, 2017 we changed the name of HubCentrix, Inc. to HealthDatix, Inc.

On April 5, 2017, the Company, through its wholly owned subsidiary HealthDatix, Inc. (“HealthDatix”) consummated the acquisition of certain assets of the CyberCare Health Network Division from EncounterCare Solutions Inc. (ECSL) in accordance with an Asset Purchase Agreement (the “Agreement”) by and among, HealthDatix, ECSL and the Company. Pursuant to the Agreement, ECSL will sell, convey, transfer and assign to HealthDatix certain assets (the “Assets”), and HealthDatix will purchase and accept from the ECSL all right, title and interest in and to the Assets in exchange for sixty million 60,000,000 shares of restricted common stock of iGambit.

The ECSL Agreement was disclosed on the Company’s current report on Form 8-K filed on April 6, 2017.

On June 30, 2017, (effective March 31, 2017) we completed the sale of ArcMail to Rory T. Welch, the CEO of ArcMail (“Welch”) in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and Welch. Pursuant to the Stock Purchase, the total consideration paid for the outstanding capital stock of ArcMail is remittance of 10,000,000 shares of iGambit common stock previously issued to Welch. As per the Purchase Agreement, the Company’s operations of ArcMail ended March 31, 2017 and Welch’s operation of the business is effective as of April 1, 2017

The ArcMail Agreement was disclosed on the Company’s current report on Form 8-K filed on July 5, 2017.

### OUR COMPANY

### Introduction

iGambit is a company focused on the medical technology markets. Our primary focus is the expansion of our subsidiary HealthDatix™ Inc.

HealthDatix is a medical technology company that provides end to end Software-as-a-Service solutions, services and products via our HealthDatix Platform that manages, reports, and analyzes critical data, enabling healthcare and commercial organizations to deliver positive member outcomes.

### HealthDatix Platform Products and Services

#### Health Risk Assessment (HRA)

Our Health Risk Assessment (HRA) solution is a standardized method of collecting health risk data from patients or employees that can be used by Wellness Clinics, Insurance Companies, Third Party Administrators (TPA’s) and/or self insured companies to identify the health risks of their employee or patient population. Our HRA solution can be tailored to deliver the HRA and a Preventive Plan for all beneficiaries and their dependents.

Target Market : Insurance Companies, TPA’s and/or self-insured companies.

#### Annual Wellness Visit (AWV)

Our Annual Wellness Visit (AWV) solution allows for a mass check of patients with CMS to determine if and when they are eligible for an initial or subsequent AWV and identifies eligibility for other preventive screenings. Our proprietary algorithm determines a patients’ qualification for preventive screenings, health and lifestyle risks and if they have 2 or more qualifying chronic conditions that make them eligible for CCM. The program creates a 5-10 year preventive plan for the patient and meets all of CMS audit requirements to bill for the services. The AWV provides a proactive approach to patient care and increases practice revenue by identifying and executing CMS recommended screenings for the patient to catch early disease states before they become chronic conditions

Target Market: Medicare Programs including ACO’s, Primary Care Offices, Chronic Care Management and Non-Medicare including Wellness Clinics, Insurance Companies, Medicare Advantage Plans (MAP)

#### BioDatix HealthBand

Our BioDatix Health Band requires our Remote Patient Monitoring (RPM) solution that speaks to our FDA cleared Electronic House Call system. The BioDatix Health Band passively collects heart rate, blood pressure, blood oxygen every 15 minutes. It calculates sleep and steps and sends to our BioDatix iOS/Android app and then to our RPM solution.

Target Markets: Physician Groups, ACO’s, Healthcare Systems, Cardiovascular & Pulmonary Providers, Insurance Companies, Preventive Care for High Stress Jobs, Wellness Clinics.

#### BioDatix Remote Patient Monitoring

In addition to our BioDatix HealthBand, our RPM solution accepts data from multiple FDA approved devices on a patient’s health status, ie. blood pressure, weight, glucose levels, etc. It’s a product that is primarily for home bound patients that need remote monitoring vs. placement in a rehab center after hospital discharge. The information in our RPM solution can then be accessed by the physician/staff to determine the health status of the patient and whether or not a critical situation is at hand for the patient to go to the hospital, come in for a visit, or receive a nursing staff visit.

Target Markets: Physician Groups, ACO’s, Healthcare Systems, Cardiovascular & Pulmonary Providers, Insurance Companies, Preventive Care for High Stress Jobs, Wellness Clinics.

#### HealthDatix - Chronic Care Management (CCM) Program

Centers for Medicaid and Medicare Services(CMS) introduced the Chronic Care Management (CCM) program in 2015 with the goal of filling patient care gaps and providing patient care at home.

HealthDatix Chronic Care Management (CCM) service was established to provide better care by engaging patients between visits by providing remote monitoring of patients. eat better, exercise more, take their medications, and live healthier lives. The CCM program delivers 20 minutes of non-face-to-face care coordination to Medicare eligible beneficiaries with two or more chronic conditions.

Target Markets: Physician Groups, ACO’s, Healthcare Systems

### Competitive Comparison

Our platform is agnostic and was developed to provide organizations with a backend solution designed to integrate with disparate wearable and non-wearable health devices, and to provide a centralized data source. The platform can tie into an organization’s existing peripherals, such as health bands, glucose meters, weight scales, temperature monitors, BP cuffs, and ECG monitors. Our HealthDatix platform collects data in an automated, secure, encrypted cloud based-platform which can be accessed by healthcare professionals, providing one centralized repository which provides trend reports and the ability to remotely triage patients.

HealthDatix Platform is built on a simple and flexible design that gives customers ownership and control over their data and offers a single comprehensive solution for Medicare compliance and data retention.

HealthDatix competes effectively against its primary competitors by providing a simple and scalable application and world-class customer support. HealthDatix’s primary competitive differentiation includes:

- Simple User Interface
- Efficient Reporting

Proprietary algorithm to generate Medicare required patient and practice reporting

- HIPAA complaint
- Fully automated and easy user data capture
- Channel Program
- First Class Customer Service

Support is provided at our U.S. headquarters by an experienced technical team

- Device agnostic

Our BioDatix differentiator from other wearables on the market is the passive collection of vitals and syncing to our RPM solution, where baseline alerts can be enabled to notify the user, designated care coordinator and the physician. The HealthDatix RPM solution creates trend reports for the physician to view and analyze. The capturing of meaningful data over the course of time paints a better picture of the overall health of the patient. Our system is not to diagnose, it is to provide the care provider with the necessary information to determine if it is medically necessary to intervene based on the data collected resulting in closer physician and patient engagement.

### Future Products and Services

HeathDatix’s product strategy is to provide additional products that will support the patients that have been identified through the program to require additional chronic care management with a medical wearable that will allow ease of use for the patient and effective tracking and management by the physician through our developed chronic care management solution.

Our next generation BioDatix device will collect ECG and temperature and will have the ability to set collection times on a per patient basis.

### Customers

HealthDatix operates by bringing on Channel Partners to sell the service to primary care Physicians, ACOs and Managed Care Practices. We currently have 5 Channel Partners with extensive sales arms through established healthcare technology companies.

### Expansion Summary

HealthDatix objective is to be a market leader in providing a world class software application as well as expand our offering to current and new channel partners.

### Employees

We presently have 6 total employees all of which are full-time for operations.

### OUR CORPORATE INFORMATION

Our principal offices are located at 1050 W. Jericho Turnpike, Suite A, Smithtown, New York, 11787. Our telephone number is (631) 670-6777 and our fax number is (516) 512-7937. We currently operate two corporate websites that can be found at www.igambit.com, and www.healthdatix.com (the information on the foregoing websites does not form a part of this report).

## Properties

As filed, 1,011 characters.

Our corporate executive office is located in Smithtown, New York, where we lease approximately 1000 square feet of office space. Monthly lease payments are approximately $1,690. The lease is for a term of two (2) years commencing on March 1, 2017 and ending on February 28, 2019. The lease contains annual escalations of 2% of the annual rent.

Our HealthDatix operations are located in St. Petersburg, Florida where we lease where office suites with furniture and equipment in the Tampa Bay Innovation Center shared coworking incubator office building. Monthly lease payments are $817 paid on a month to month basis.

Our leased properties are suitable for their respective uses and are, in general, adequate for our present needs. Our properties are subject to various federal, state, and local statutes and ordinances regulating their operations. Management does not believe that compliance with such statutes and ordinances will materially affect our business, financial condition, or results of operations.

## Legal proceedings

As filed, 276 characters.

From time-to-time, the Company is involved in various civil actions as part of its normal course of business. The Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the period ended December 31, 2018.

## Management's discussion and analysis

As filed, 22,537 characters.

### CRITICAL ACCOUNTING POLICIES

Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements may require us to make estimates and assumptions that may affect the reported amounts of assets and liabilities and the related disclosures at the date of the financial statements. We do not currently have any estimates or assumptions where the nature of the estimates or assumptions is material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change or the impact of the estimates and assumptions on financial condition or operating performance is material, except as described below.

### Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries HealthDatix, Inc. All intercompany accounts and transactions have been eliminated.

### Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

### Long-Lived Assets

We assess the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. We base our evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, we determine whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, we recognize a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

### Revenue Recognition

iGambit is a holding company and has no sources of revenue.

HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers. HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.

### Accounts Receivable

We analyze the collectability of accounts receivable from continuing operations each accounting period and adjust our allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. We evaluate specific accounts when we become aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.

### Goodwill and Intangible Assets

Goodwill represents the excess of liabilities assumed over assets acquired of HealthDatix and the fair market value of the common shares issued by the Company for the acquisition of HealthDatix. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. The Company recorded a full impairment of the Goodwill as of December 31, 2017.

### Stock-Based Compensation

We account for our stock-based awards granted under our employee compensation plan in accordance with ASC Topic No. 718-20, *Awards Classified as Equity,* which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. We use the Black-Scholes option pricing model to estimate the fair value of our stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

#### Options

In 2006, we adopted the 2006 Long-Term Incentive Plan (the "2006 Plan"). Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of December 31, 2015, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan.

The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock. 8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date. There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan.

Stock option activity during the years ended December 31, 2018 and 2017 follows:

|  | Options Outstanding | Weighted Average Exercise Price | Weighted Average Grant-Date Fair Value | Weighted Average Remaining Contractual Life (Years) |
| --- | ---: | ---: | ---: | ---: |
| Options outstanding at December 31, 2016 | 1,422,000 | $0.03 | $0.13 | 5.60 |
| Options granted | 7,800,000 | 0.07 | — |  |
| Options expired | (759,000) | 0.03 | — |  |
| Options outstanding at December 31, 2017 | 8,463,000 | 0.07 | 0.07 | 7.41 |
| Options granted | 12,250,000 | 0.01 | — |  |
| Options expired | (213,000) | 0.03 | — |  |
| Options outstanding at December 31, 2018 | 20,500,000 | $0.03 | $0.03 | 7.52 |

Options outstanding at December 31, 2018 consist of:

| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date |
| --- | ---: | ---: | ---: | --- |
| June 6, 2014 | 250,000 | 250,000 | $0.05 | June 6, 2019 |
| March 24, 2015 | 200,000 | 200,000 | $0.01 | March 24, 2020 |
| April 6, 2017 | 600,000 | 600,000 | $0.03 | April 6, 2027 |
| June 6, 2017 | 700,000 | 700,000 | $0.07 | June 6, 2022 |
| June 6, 2017 | 6,500,000 | 6,500,000 | $0.07 | June 6, 2027 |
| November 1, 2018 | 12,250,000 | 12,250,000 | $0.01 | November 1, 2028 |
| Total | 20,500,000 | 20,500,000 |  |  |

#### Warrants

In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expire on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval.

Warrant activity during the years ended December 31, 2018 and 2017 follows:

|  | Warrants Outstanding | Weighted Average Exercise Price | Weighted Average Grant-Date Fair Value | Weighted Average Remaining Contractual Life (Years) |
| --- | ---: | ---: | ---: | ---: |
| Warrants outstanding at December 31, 2016 | 275,000 | $0.94 | $0.10 | 2.42 |
| Warrant granted | 125,000 | 0.40 | — |  |
| Warrants outstanding at December 31, 2017 | 400,000 | $0.62 | $0.10 | 3.27 |
| Warrant granted | 1,500,000 | 0.05 | — |  |
| Warrant expired | (25,000) | 3.00 | — |  |
| Warrants outstanding at December 31, 2018 | 1,875,000 | $0.12 | $0.12 | 3.24 |

(1) Exclusive of 25,000 warrants expiring 2 years after initial IPO.

Warrants outstanding at December 31, 2018 consist of:

| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date |
| --- | ---: | ---: | ---: | --- |
| June 1, 2009 | 100,000 | 100,000 | $0.50 | June 1, 2019 |
| June 1, 2009 | 50,000 | 50,000 | $0.65 | June 1, 2019 |
| June 1, 2009 | 50,000 | 50,000 | $0.85 | June 1, 2019 |
| June 1, 2009 | 50,000 | 50,000 | $1.15 | June 1, 2019 |
| January 1, 2017 | 50,000 | 50,000 | $0.25 | October 10, 2021 |
| January 1, 2017 | 50,000 | 50,000 | $0.50 | November 7, 2021 |
| January 5, 2017 | 25,000 | 25,000 | $0.50 | January 5, 2022 |
| February 5, 2018 | 750,000 | 750,000 | $0.05 | February 5, 2023 |
| April 27, 2018 | 750,000 | 750,000 | $0.05 | April 27, 2023 |
| Total | 1,875,000 | 1,875,000 |  |  |

### Convertible Debenture

We issued convertible debentures to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.05 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the period. Interest expense on the convertible debentures of $8,616 and $8,782 was recorded for the years ended December 31, 2018 and 2017, respectively

### Income Taxes

We follow Accounting Standards Codification subtopic 740, *Income Taxes (“*ASC 740”) which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred taxes are classified as current or non-current, depending on the classification of the assets and liabilities to which they relate.

### MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Introduction

iGambit is a company focused on the medical technology markets. Our primary focus is the expansion of our newly acquired medical technology business HealthDatix Inc.

### Year Ended December 31, 2018 as Compared to Year Ended December 31, 2017

***Assets.*** At December 31, 2018, we had $42,313 in current assets and $2,618,466 in total assets, compared to $55,080 in current assets and $3,328,755 in total assets as of December 31, 2017. There was a decrease in current assets from the reduction of prepaid expenses and cash, and there was a decrease in total assets as a result of amortization of intangible assets.

***Liabilities.*** At December 31, 2018, we had total liabilities of $1,385,447 compared to $959,780 at December 31, 2017. Our total liabilities at December 31, 2018 consisted of current liabilities including accounts payable and accrued expenses of $480,270, accrued interest on notes payable of $32,265, amounts due to related parties of $145,367, deferred revenue of $9,192, notes payable of $52,500, convertible debentures of $377,611 and derivative liability of $288,242, whereas our total liabilities at December 31, 2017 consisted of current liabilities including accounts payable and accrued expenses of $348,354, accrued interest on notes payable of $21,602, amounts due to related parties of $128,476, deferred revenue of $9,100, notes payable of $52,500, convertible debentures of $333,689 and derivative liability of $66,059. We had no long-term liabilities for the years ended December 31, 2018 and December 31, 2017, respectively. The increase in liabilities was primarily due to an increase in accounts payable and accrued expenses, an increase in amounts due to related parties, and increase in convertible debentures and an increase in derivative liability.

***Stockholders’ Equity.*** Our Stockholders’ Equity was $1,233,019 at December 31, 2018 compared to $2,368,975 at December 31, 2017. This decrease was due to an increase in accumulated deficit from $(9,648,569) at December 31, 2017 to $(12,462,814) at December 31, 2018, resulting from a net loss of $(2,814,245).

***Net Income (Loss).*** We had a loss from continuing operations of $(2,814,245) and $(6,007,474) for the years ended December 31, 2018 and December 31, 2017, respectively, and income from discontinued operations of $0 and $6,589,536 for the years ended December 31, 2018 and December 31, 2017, respectively.

***General and Administrative Expenses.*** General and Administrative Expenses decreased to $1,163,766 for the year ended December 31, 2018 from $1,813,624 for the year ended December 31, 2017. For the year ended December 31, 2018, our General and Administrative Expenses consisted of corporate administrative expenses of $75,122, legal and accounting fees of $139,087, payroll expenses of $522,173, employee benefits expenses of $39,785 (medical and life insurance), filing fees of $21,207, marketing expense of $42,394, automobile expense of $19,260, computer software licensing expense of $14,229 finder’s fees and commissions expense of $29,000, consulting fees of $103,400, transfer agent expense of $38,178, rent expense of $28,885, contract labor expense of $52,034, travel and entertainment expense of $23,012 and board compensation expense of $16,000. For the year ended December 31, 2017, our General and Administrative Expenses consisted of corporate administrative expenses of $97,886, legal and accounting fees of $185,880, payroll expenses of $709,399, employee benefits expenses of $55,077 (medical and life insurance), filing fees of $19,756, financing expense of $15,000, marketing expense of $69,048, advertising expense of $2,517, finder’s fees and commissions expense of $84,475, consulting fees of $373,136, transfer agent expense of $14,204, rent expense of $26,745, research and development expense of $25,645 and board compensation expense of $134,856. Therefore, the decreases from the year ended December 31, 2018 to the year ended December 31, 2017 relate primarily to a decrease in legal and accounting expense, payroll, board compensation, filing fees, consulting expenses, and research and development expenses. In 2019 we anticipate an increase in general administrative expenses associated with expansion of our HealthDatix subsidiary.

### LIQUIDITY AND CAPITAL RESOURCES

### General

As reflected in the accompanying consolidated financial statements, at December 31, 2018, we had $369 of cash and stockholders’ equity of $1,233,019. At December 31, 2017, we had $9,449 of cash and stockholders’ equity of $2,368,975.

Our primary capital requirements in 2019 are likely to rise from the expansion of our HealthDatix operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

### Cash Flow Activity

Net cash used in operating activities was $765,471 for the year ended December 31, 2018, compared to $714,623 for the year ended December 31, 2017. Net cash used in continuing operating activities was $765,471 for the year ended December 31, 2018, compared to $705,407 for the year ended December 31, 2017. Our primary use of cash flows from continuing operating activities was from net losses of $2,814,245 and $6,007,474 from continuing operations for the years ended December 31, 2018 and 2017, respectively. Additional contributing factors to the change were from depreciation of $1,727, amortization of $695,870, non-cash interest expense of $638,718, stock-based compensation expense of $208,025, loss on extinguishment of debt of $312,869, change in fair value of derivative liability of $28,745, an increase in accounts receivable of $8,617, a decrease in inventory of $127, a decrease in prepaid expenses of $39,377, an increase in deposits of $75, an increase in accounts payable and accrued expenses of $131,916, and an increase in deferred revenue of $92. Net cash used in discontinued operating activities was $0 and $9,216 for the years ended December 31, 2018 and 2017, respectively. Cash used in discontinued operating activities for the year ended December 31, 2017 consisted of $9,216 in cash payments applied against accounts receivable that had been included in assets from discontinued operations.

Cash provided by investing activities was $0 and $2,050 for the years ended December 31, 2018 and December 31, 2017, respectively. Net cash used in continuing investing activities was $0 and $30,798 for the years ended December 31, 2018 and 2017, respectively. For the year ended December 31, 2017, the primary uses of cash from continuing investing activities was from, pre-acquisition loans to subsidiary of $50,000, loans to deconsolidated subsidiary of $10,382, and cash acquired from acquisition of subsidiary of $29,584. Net cash provided by discontinued investing activities was $0 and $32,848 for the years ended December 31, 2018 and 2017, respectively.

Cash provided by financing activities was $756,391 for the year ended December 31, 2018 compared to $711,500 for the year ended December 31, 2017. Net cash provided by continuing financing activities was $756,391 for the year ended December 31, 2018 and $735,492 for the year ended December 31, 2017. The cash flows provided by continuing financing activities for the year ended December 31, 2018 was from $709,500 in proceeds from convertible debentures, $30,000 in proceeds from the sale of common stock, $32,491 in proceeds from related party loans, and repayments of related party loans of $(15,600). The cash flows provided by continuing financing activities for the year ended December 31, 2017 was from $469,000 in proceeds from convertible debentures, $275,000 in proceeds from the sale of common stock, repayments of related party loans of $(508), and repayment of notes payable of $(8,000). Net cash used in discontinued financing activities was $0 and $23,992 for the years ended December 31, 2018 and 2017, respectively.

### Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

### OFF BALANCE SHEET ARRANGEMENTS

We have no off balance-sheet arrangements.

## Controls and procedures

As filed, 2,554 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Annual Report on Form 10-K.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of December 31, 2018, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2018.

**Limitations on Effectiveness of Controls and Procedure**s

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Filed Apr 16, 2019.
Source: SEC EDGAR, the filing index for accession 0001607062-19-000159. Last ingested by Listed: Nov 14, 2026, 12:46 ET. No prices; not investment advice.
